Last reviewed · How we verify

NCT06897566: BOLT

Barriers to Optimal LDL-C Targets in Patients With Atherosclerotic Cardiovascular Disease

Completed Last updated 3 December 2025
What this trial tests

trial testing Fasting lipid profile in Coronary Artery Disease in 1,000 participants. Completed in 1 November 2025.

Timeline
21 September 2024
Primary endpoint
1 November 2025
1 November 2025

Quick facts

Lead sponsorCairo University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,000
Start date21 September 2024
Primary completion1 November 2025
Estimated completion1 November 2025
Sites2 locations across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Cairo University

Who can join

Adults 18 to 80, any sex, with Coronary Artery Disease or Statin Adverse Reaction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In the present cross-sectional observational study, the investigators aimed to: * Evaluate the prevalence of achievement of LDL-C targets among a sample of Egyptian ASCVD patients. * Attempt to unveil the potential barriers to achieve LDL-C goals in order to determine the appropriate corrective actions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

Other Cairo University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06897566.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing